Does low-dose naltrexone help with fibromyalgia pain?

Low-Dose Naltrexone for Fibromyalgia Pain

Low-dose naltrexone (LDN) shows modest benefit for fibromyalgia pain compared to placebo, but the evidence is mixed and the effect size is small; it should be considered only as a second- or third-line option after established first-line therapies (duloxetine, milnacipran, pregabalin, and exercise) have failed or are not tolerated. 1, 2

Guideline-Based Treatment Hierarchy

First-Line Therapies (Use These First)

• Duloxetine 60 mg daily is the preferred pharmacologic agent with FDA approval and strong guideline support for fibromyalgia, particularly when depression coexists 2
• Exercise is the only therapy with a "strong for" recommendation based on meta-analyses 1
• Pregabalin and gabapentin are FDA-approved anticonvulsants with established efficacy 3, 4
• Amitriptyline 25–50 mg at bedtime is recommended as a second-line option when SNRIs are contraindicated, though it should be avoided in patients ≥65 years due to anticholinergic effects 4, 2

Where LDN Fits in the Algorithm

LDN is mentioned in one ophthalmology guideline as an off-label option for neuropathic pain conditions including fibromyalgia, but it is not included in major rheumatology or pain management guidelines (EULAR 2017, CDC 2016) as a recommended therapy 5, 4, 1

Evidence for LDN in Fibromyalgia

Positive Findings

• A 2025 meta-analysis of 5 RCTs showed LDN reduced pain scores compared to placebo (SMD -0.61; 95% CI -1.14 to -0.08), with sensitivity analysis strengthening this finding (SMD -0.87; 95% CI -1.28 to -0.46) 6
• A 2024 Korean meta-analysis of 4 RCTs (222 patients) found significant pain reduction (MD -0.86; 95% CI -1.20 to -0.51) and increased pressure pain threshold (MD 0.17; 95% CI 0.08 to 0.25) 7
• A 2025 meta-analysis focusing on fibromyalgia specifically found LDN superior to placebo in this condition (d = -0.34; 95% CI -0.62 to -0.06) 8
• One small RCT (n=31) using LDN 4.5 mg showed significant decrease in pain and improved life satisfaction versus placebo 5

Negative or Equivocal Findings

• The highest-quality and most recent trial (2024, published in The Lancet Rheumatology) randomized 99 women with fibromyalgia to LDN 6 mg or placebo for 12 weeks and found no significant difference in pain reduction: mean change -1.3 points (LDN) vs -0.9 points (placebo), between-group difference -0.34 (95% CI -0.95 to 0.27; p=0.27, Cohen's d 0.23) 9
• A 2023 Danish crossover RCT (n=58) found no clinically relevant analgesic efficacy: median FIQR difference -1.65 (effect size 0.15; P=0.3) and SPIR difference -0.33 (effect size 0.13; P=0.4) 10
• A 2023 systematic review concluded that while LDN may be effective, "the level of scientific evidence is limited" and called for larger, well-designed trials 11

Reconciling Contradictory Evidence

The most recent, highest-quality single trial published in a prestigious journal (The Lancet) showed no benefit, while meta-analyses of smaller, older trials suggest modest benefit. This discrepancy likely reflects publication bias in earlier small studies and highlights that the true effect size is at best small and may not be clinically meaningful 9, 7

Dosing Protocol (If Used)

Based on the ophthalmology guideline and research protocols 5, 9, 10:

• Start at 1.5 mg at bedtime, increase by 1.5 mg every 2 weeks to a maximum of 4.5 mg at bedtime 5
• Alternative: Start at 4.5 mg once daily (used in most RCTs) 6, 7
• One trial used 6 mg daily 9
• Treatment duration in trials ranged from 8–12 weeks 6, 9, 10

Safety Profile

Common Adverse Events

• Vivid dreams are significantly more common with LDN (RR 2.41; 95% CI 1.77 to 3.28) 6
• Nausea is increased with LDN 7
• Headache, tachycardia, and insomnia may occur 5
• Overall adverse event rate is 84–86%, similar to placebo, with discontinuation rates of 6–8% 9

Serious Risks (From FDA Label)

• Hepatotoxicity: At doses 5-fold higher than recommended (300 mg/day), naltrexone caused hepatocellular injury in a substantial proportion of patients; this has not been observed at low doses (4.5 mg), but caution is warranted 12
• Precipitated opioid withdrawal: Patients must be opioid-free (including tramadol) for 7–10 days before starting naltrexone 12
• The FDA label does not support use of naltrexone for fibromyalgia; approved indications are opioid dependence and alcoholism 12

Clinical Algorithm for LDN Use

Step 1: Ensure patient has failed or cannot tolerate first-line therapies:

• Duloxetine 60–120 mg daily 2
• Pregabalin 300–450 mg daily 3
• Structured aerobic exercise program 1

Step 2: Consider second-line options before LDN:

• Milnacipran (FDA-approved for fibromyalgia) 2
• Amitriptyline 25–50 mg at bedtime (if <65 years and no cardiac disease) 4, 2
• Gabapentin 1800–3600 mg daily 13
• Multimodal rehabilitation and cognitive-behavioral therapy 1

Step 3: If considering LDN as a third-line option:

• Confirm patient is opioid-free for ≥7 days (including tramadol) 12
• Discuss that evidence is mixed, with the highest-quality trial showing no benefit 9
• Start 1.5–4.5 mg at bedtime 5
• Trial duration: 8–12 weeks 6, 10
• Monitor for vivid dreams, nausea, and lack of efficacy 6, 7

Step 4: Discontinue if no meaningful improvement after 12 weeks, as this is an off-label use with uncertain benefit 9, 10, 11

Key Caveats

• LDN is not FDA-approved for fibromyalgia and is not mentioned in major fibromyalgia guidelines (EULAR 2017, CDC 2016) 4, 1, 12
• The most recent, highest-quality evidence shows no benefit over placebo 9
• Meta-analyses suggest a small effect, but this may reflect publication bias from earlier small trials 6, 7, 8
• Effect size is small even in positive meta-analyses (Cohen's d 0.23–0.34), which is below the threshold for clinical significance 9, 8
• One case report describes sustained benefit over 2 years, but this is anecdotal evidence 14
• Strong opioids and chronic opioid therapy are explicitly not recommended for fibromyalgia 3, 4, 1

Practical Pitfall to Avoid

Do not use LDN as a first-line agent or before exhausting guideline-recommended therapies. The temptation to try LDN based on patient request or internet information should be resisted until duloxetine, pregabalin, exercise, and multimodal therapy have been attempted, as these have far stronger evidence 1, 2, 9